| abstract |
The present invention relates to methods for improving the efficacy of therapies involving immune effector cells, such as T cells engineered to express antigen receptors, such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). If a target antigen for an antigen receptor is additionally provided to the subject, these antigen receptor engineered immune effector cells are difficult to treat with disease such as cancer, even with antigen receptor engineered immune effector cells, even when provided to the subject in a subtherapeutic amount. It has been demonstrated herein to be highly effective in the treatment of diseases such as cancers, such as solid tumors or solid cancers. Immune effector cells can be engineered ex vivo or in vitro, and then the immune effector cells can be administered to a subject in need of treatment, or the immune effector cells can be engineered in vivo in a subject in need of treatment. |